The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy
Abstract
BACKGROUND: Quetiapine is a new atypical antipsychotic medication. As such, relatively little has been published regarding its in vivo effects at the dopamine type 2 (D2) and serotonin type 2a (5-HT2a) receptor systems. The following study was undertaken to explore these effects across the clinical dose range and relate this information to its clinical profile. METHODS: Twelve patients with schizophrenia were randomly assigned to doses of 150 to 600 mg/d (n=3, at 150, 300, 450, and 600 mg/d) of quetiapine. After 3 weeks of treatment, D2 and 5-HT2a occupancy were measured using positron emission tomography (PET) imaging, 12 to 14 hours after the last dose. Clinical efficacy and adverse effect ratings were obtained at baseline, at the time of PET scanning, and at 12 weeks. Two additional patients were included to examine the effects of the drug 2 to 3 hours after last dose. RESULTS: Quetiapine was an effective antipsychotic and improved the extrapyramidal symptoms and prolactin level elevation noted at baseline. It achieved these results with minimal (0%-27%) D2 occupancy 12 hours after the last dose. Study of the additional subjects revealed that quetiapine does give rise to transiently high (58%-64%) D2 occupancy 2 to 3 hours after a single dose that then decreases to minimal levels in 12 hours. CONCLUSIONS: Quetiapine shows a transiently high D2 occupancy, which decreases to very low levels by the end of the dosing interval. Quetiapine's low D2 occupancy can explain its freedom from extrapyramidal symptoms and prolactin level elevation. The data suggest that transient D2 occupancy may be sufficient for its antipsychotic effect. Future studies controlling for nonpharmacological effects as well as activities on other receptors will be necessary to confirm this suggestion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
(1976) · Medical Entomology and Zoology · Cited by 8,899
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Self-citationSerotonin-dopamine interaction and its relevance to schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 823
Arvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 803
Kapur, S., Zipursky, R. B., & Remington, G. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 712
Self-citationQuetiapine in Patients With Schizophrenia: A High- and Low-Dose Double-blind Comparison With Placebo
Small, J. G. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180067009 · Cited by 478
5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370
Self-citationSeeman, P., & Tallerico, T. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000336 · Cited by 301
Seroquel: biochemical profile of a potential atypical antipsychotic
Saller, C. F., & Salama, A. I. (1993) · Psychopharmacology · doi:10.1007/bf02244923 · Cited by 269
A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
Peuskens, J., & Link, C. G. G. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb10162.x · Cited by 251
Ögren, S. O., Hall, H., Köhler, C., Magnusson, O., Lindbom, L.-O., Ängeby, K., & Florvall, L. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90567-3 · Cited by 212
Farde, L., Suhara, T., Karlsson, P., Hietala, J., Nakashima, Y., Halldin, C., & Nyberg, S. (1997) · Psychopharmacology · doi:10.1007/s002130050420 · Cited by 177
Limbic selectivity of clozapine
Pilowsky, L. S., Mulligan, R. S., Acton, P. D., Ell, P. J., Costa, D. C., & Kerwin, R. W. (1997) · The Lancet · doi:10.1016/s0140-6736(05)63079-6 · Cited by 173
Stockmeier, C. A., DiCarlo, J. J., Zhang, Y., Thompson, P., & Meltzer, H. Y. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39339-0 · Cited by 170
Gefvert, O., Bergström, M., Långström, B., Lundberg, T., Lindström, L., & Yates, R. (1998) · Psychopharmacology · doi:10.1007/s002130050492 · Cited by 169
D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate
Nyberg, S., Farde, L., Halldin, C., Dahl, M., & Bertilsson, L. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.173 · Cited by 143
Puech, A. J., Fleurot, O., Rein, W., & Amisulpride Study Group (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb10044.x · Cited by 143
Blin, J., Sette, G., Fiorelli, M., Blétry, O., Elghozi, J. L., Crouzel, C., & Baron, J. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01229.x · Cited by 107
Lewis, R., Kapur, S., Jones, C., DaSilva, J. N., Brown, G. M., Wilson, A. A., Houle, S., & Zipursky, R. B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.72 · Cited by 101
Self-citationPlacebo-Controlled Study of the D4/5-HT2A Antagonist Fananserin in the Treatment of Schizophrenia
Truffinet, P., Tamminga, C. A., Fabre, L. F., Meltzer, H. Y., re, M.-E. R. ⁄., & Papillon-Downey, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.3.419 · Cited by 94
Blin, J., Pappatà, S., Kiyosawa, M., Crouzel, C., & Baron, J. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90635-8 · Cited by 94
Plasma Prolactin and Central D2 Receptor Occupancy in Antipsychotic Drug-Treated Patients
Nordström, A., & Farde, L. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00010 · Cited by 70
Freeman, H. L. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705002-00004 · Cited by 55
Andrée, B., Nyberg, S., Ito, H., Ginovart, N., Brunner, F., Jaquet, F., Halldin, C., & Farde, L. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00012 · Cited by 45
Pilowsky, L. S., O'Connell, P., Davies, N. A., et al. (1997) · Psychopharmacology · doi:10.1007/s002130050223 · Cited by 43
Neuroleptics have identical potencies in human brain limbic and putamen regions
Seeman, P. M., & Ulpian, C. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90452-1 · Cited by 43
Kapur, S., JONES, C., DaSilva, J. N., Wilson, A. A., & Houle, S. (1997) · Nuclear Medicine Communications · doi:10.1097/00006231-199705000-00002 · Cited by 30
Self-citationTauscher, J. T., Kufferle, B., Asenbaum, S., Brücke, T., & Kasper, S. F. (1997) · Psychopharmacology · doi:10.1007/s002130050378 · Cited by 18
Receptor Occupancy by Antipsychotics — Concepts and Findings
Kapur, S. (2000) · Handbooks of pharmacology and toxicology · doi:10.1201/9781420041774.ch11 · Cited by 13
Self-citation
Cited by
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Self-citationMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Half a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638
Self-citationMiyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Metadata
- Authors
- Kapur, S.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2000-06-01
- Volume
- 57
- Issue
- 6
- Pages
- 553-559
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2009915820
- Cited by
- 396
- References
- 36
- FWCI
- 15.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.